Zuellig Pharma

AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD

Featured products of Amgen
adalimumab
Packing/Price
2's, 4's, 6's, 1's
MIMS Class
Disease-Modifying Anti-Rheumatic Drugs (DMARDs), Immunosuppressants
ATC Classification
L04AB04 - adalimumab : Belongs to the class of tumor necrosis factor alpha (TNF-alpha) inhibitors. Used as immunosuppressants.
adalimumab
Packing/Price
1's
MIMS Class
Disease-Modifying Anti-Rheumatic Drugs (DMARDs), Immunosuppressants
ATC Classification
L04AB04 - adalimumab : Belongs to the class of tumor necrosis factor alpha (TNF-alpha) inhibitors. Used as immunosuppressants.
adalimumab
Packing/Price
6's, 1's, 2's, 4's
MIMS Class
Disease-Modifying Anti-Rheumatic Drugs (DMARDs), Immunosuppressants
ATC Classification
L04AB04 - adalimumab : Belongs to the class of tumor necrosis factor alpha (TNF-alpha) inhibitors. Used as immunosuppressants.
blinatumomab
Packing/Price
1's
MIMS Class
Targeted Cancer Therapy
ATC Classification
L01XC19 - blinatumomab : Belongs to the class of monoclonal antibodies, other antineoplastic agents. Used in the treatment of cancer.
carfilzomib
Packing/Price
1's
MIMS Class
Targeted Cancer Therapy
ATC Classification
L01XG02 - carfilzomib : Belongs to the class of proteasome inhibitors. Used in the treatment of cancer.
pegfilgrastim
Packing/Price
0.6 mL x 1's
MIMS Class
Haematopoietic Agents, Supportive Care Therapy
ATC Classification
L03AA13 - pegfilgrastim : Belongs to the class of colony stimulating factors. Used as immunostimulants.
filgrastim
Packing/Price
0.5 mL x 1's
MIMS Class
Haematopoietic Agents, Supportive Care Therapy
ATC Classification
L03AA02 - filgrastim : Belongs to the class of colony stimulating factors. Used as immunostimulants.
etelcalcetide hydrochloride
Packing/Price
10 × 1's
MIMS Class
Other Agents Affecting Metabolism
ATC Classification
H05BX04 - etelcalcetide : Belongs to the class of other anti-parathyroid agents. Used in the management of calcium homeostasis.
etelcalcetide hydrochloride
Packing/Price
10 × 1's
MIMS Class
Other Agents Affecting Metabolism
ATC Classification
H05BX04 - etelcalcetide : Belongs to the class of other anti-parathyroid agents. Used in the management of calcium homeostasis.
denosumab
Packing/Price
1's
MIMS Class
Agents Affecting Bone Metabolism
ATC Classification
M05BX04 - denosumab : Belongs to the class of other drugs affecting bone structure and mineralization. Used in the treatment of bone diseases.
evolocumab
Packing/Price
(autoinjector) 1's, 1's
MIMS Class
Dyslipidaemic Agents
ATC Classification
C10AX13 - evolocumab : Belongs to the class of other lipid modifying agents.
panitumumab
Packing/Price
1's
MIMS Class
Targeted Cancer Therapy
ATC Classification
L01XC08 - panitumumab : Belongs to the class of monoclonal antibodies, other antineoplastic agents. Used in the treatment of cancer.
denosumab
Packing/Price
1's
MIMS Class
Agents Affecting Bone Metabolism
ATC Classification
M05BX04 - denosumab : Belongs to the class of other drugs affecting bone structure and mineralization. Used in the treatment of bone diseases.
Distributed by Zuellig Pharma
adalimumab
Packing/Price
2's, 4's, 6's, 1's
MIMS Class
Disease-Modifying Anti-Rheumatic Drugs (DMARDs), Immunosuppressants
ATC Classification
L04AB04 - adalimumab : Belongs to the class of tumor necrosis factor alpha (TNF-alpha) inhibitors. Used as immunosuppressants.
adalimumab
Packing/Price
1's
MIMS Class
Disease-Modifying Anti-Rheumatic Drugs (DMARDs), Immunosuppressants
ATC Classification
L04AB04 - adalimumab : Belongs to the class of tumor necrosis factor alpha (TNF-alpha) inhibitors. Used as immunosuppressants.
adalimumab
Packing/Price
6's, 1's, 2's, 4's
MIMS Class
Disease-Modifying Anti-Rheumatic Drugs (DMARDs), Immunosuppressants
ATC Classification
L04AB04 - adalimumab : Belongs to the class of tumor necrosis factor alpha (TNF-alpha) inhibitors. Used as immunosuppressants.
blinatumomab
Packing/Price
1's
MIMS Class
Targeted Cancer Therapy
ATC Classification
L01XC19 - blinatumomab : Belongs to the class of monoclonal antibodies, other antineoplastic agents. Used in the treatment of cancer.
carfilzomib
Packing/Price
1's
MIMS Class
Targeted Cancer Therapy
ATC Classification
L01XG02 - carfilzomib : Belongs to the class of proteasome inhibitors. Used in the treatment of cancer.
pegfilgrastim
Packing/Price
0.6 mL x 1's
MIMS Class
Haematopoietic Agents, Supportive Care Therapy
ATC Classification
L03AA13 - pegfilgrastim : Belongs to the class of colony stimulating factors. Used as immunostimulants.
filgrastim
Packing/Price
0.5 mL x 1's
MIMS Class
Haematopoietic Agents, Supportive Care Therapy
ATC Classification
L03AA02 - filgrastim : Belongs to the class of colony stimulating factors. Used as immunostimulants.
etelcalcetide hydrochloride
Packing/Price
10 × 1's
MIMS Class
Other Agents Affecting Metabolism
ATC Classification
H05BX04 - etelcalcetide : Belongs to the class of other anti-parathyroid agents. Used in the management of calcium homeostasis.
etelcalcetide hydrochloride
Packing/Price
10 × 1's
MIMS Class
Other Agents Affecting Metabolism
ATC Classification
H05BX04 - etelcalcetide : Belongs to the class of other anti-parathyroid agents. Used in the management of calcium homeostasis.
denosumab
Packing/Price
1's
MIMS Class
Agents Affecting Bone Metabolism
ATC Classification
M05BX04 - denosumab : Belongs to the class of other drugs affecting bone structure and mineralization. Used in the treatment of bone diseases.
evolocumab
Packing/Price
(autoinjector) 1's, 1's
MIMS Class
Dyslipidaemic Agents
ATC Classification
C10AX13 - evolocumab : Belongs to the class of other lipid modifying agents.
panitumumab
Packing/Price
1's
MIMS Class
Targeted Cancer Therapy
ATC Classification
L01XC08 - panitumumab : Belongs to the class of monoclonal antibodies, other antineoplastic agents. Used in the treatment of cancer.
denosumab
Packing/Price
1's
MIMS Class
Agents Affecting Bone Metabolism
ATC Classification
M05BX04 - denosumab : Belongs to the class of other drugs affecting bone structure and mineralization. Used in the treatment of bone diseases.

Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in